HilleVax (HLVX) Expected to Announce Quarterly Earnings on Thursday

HilleVax (NASDAQ:HLVX) is expected to be releasing its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect HilleVax to post earnings of ($0.37) per share for the quarter.

HilleVax (NASDAQ:HLVX) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.02). On average, analysts expect HilleVax to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

HilleVax Trading Down 2.0 %

HilleVax stock opened at $1.92 on Tuesday. The company has a market capitalization of $96.27 million, a P/E ratio of -0.62 and a beta of 0.78. HilleVax has a 1-year low of $1.34 and a 1-year high of $16.31. The firm’s fifty day simple moving average is $1.70 and its 200-day simple moving average is $1.84.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating and issued a $2.00 target price on shares of HilleVax in a research note on Monday, March 31st. Six investment analysts have rated the stock with a hold rating, According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $3.00.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.